National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

NA17-A antigen
A specific melanoma antigen protein derived from a patient (NA17) with cutaneous melanoma metastases. When administered in a vaccine formulation, NA17-A antigen may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. The NA17-A antigen is part of the enzyme N-acetyl glucosaminyl-transferase V (GnT-V). Approximately half of melanomas have been found to express significant levels of this atypical protein, which is not expressed by normal tissues. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonym:NA17-A



Previous:Mylotarg, Mylovenge, Myochrysine, N-methylformamide, N-phosphonacetyl-L-aspartate
Next:nabilone, nadroparin calcium, NAE inhibitor MLN4924, nafoxidine hydrochloride, naloxone hydrochloride

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov